NR1D1 and Obesity: We have shown that activation of intestinal REV-ERBα by SR9009 (a synthetic agonist) down-regulates BMAL1 expression in the intestine to reduce fat absorption and ameliorate HFD-induced obesity (Fig. 8), providing a unique strategy for obesity prevention and control.